Skip to content
DataLookout
Menu

NCT07638566

A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

StatusWithdrawn
PhasePhase 2/3
Sponsorargenx
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Stopped Withdrawn before enrolling Sponsor's reason: An alternative study design is under consideration.
    • Enrollment target: estimated 6 to confirmed 0
    • Eligibility criteria expanded, about 7 words
    • Primary endpoints: details revised at 1 of 2 entries
  2. Study First Submitted
  • Stopped: terminated, suspended or withdrawn

Endpoints

Primary

Empasiprubart serum concentrations as input for a population PK-driven analysis to determine the effect of age and body size on CL and Vd
Timeframe: Up to 8 weeks
Free and total C2 levels as input for PK/PD modeling analysis
Timeframe: Up to 8 weeks

Secondary (4)

Incidence of AEs, SAEs and AESIs
Empasiprubart serum concentrations over time
Percentage reductions from baseline of free and total C2 levels over time
Incidence of ADA and NAb against empasiprubart in serum

Arms and interventions

Empasiprubart IVExperimental

Participants will receive empasiprubart IV

Biologicals: Empasiprubart IV